EULAR 2026 Daily Podcast Day 4c
From Rheumnow Podcast by Dr. Cush
June 8, 2026 · 25 min · Episode 1499
About this episode
This episode discusses the efficacy of Guselkumab across the PsA disease spectrum and reviews various trials related to inflammatory arthritis treatments.
Guselkumab Delivers Across the PsA Disease Spectrum: APEX TrialRA BRIDGE and RA BRANCH trials: Baricitinib and VTE RiskImproving Referrals for Inflammatory Arthritis"Combination Therapy: Off the Shelf Allogenic NK and Rituximab in Rheumatic Disease
People in this episode
Host: Dr. Cush
Topics covered
- PsA Disease Spectrum
- Inflammatory Arthritis
- Combination Therapy
- Rheumatic Disease
- VTE Risk
Keywords
- Guselkumab
- PsA
- Baricitinib
- RA BRIDGE
- RA BRANCH
- Rituximab
- VTE Risk
- Combination Therapy
- Inflammatory Arthritis
Mentioned in this episode
Organizations: EULAR
Products: Guselkumab, Baricitinib, Rituximab
More episodes of Rheumnow Podcast
- RheumNow EULAR 2026 Rheumatology Round Up · June 12, 2026 · 56 min
- EULAR 2026 RA Topic Panel · June 11, 2026 · 54 min
- CAR-T Topic Panel EULAR 2026 · June 10, 2026 · 38 min
- EULAR 2026 PsA Update What's Changing in Psoriatic Arthritis Care? · June 9, 2026 · 49 min
- RA Topic Podcast compilation · June 8, 2026 · 1h 35m
- PsA Topic Podcast compilation · June 8, 2026 · 1h 37m
Explore listener stats, chart rankings, contacts and more on the Rheumnow Podcast podcast page.